Category Archives: Cardiovascular Pharmacology

According to the Heart Foundation, more than three million Australian women have high cholesterol, placing them at greater risk of heart attack or stroke. Continue reading →

Gastrointestinal (GI) bleeding is a common problem affecting approximately 150 patients per 100,000 population in the United States and the United Kingdom and has a mortality rate of 5% to 10%. GI bleeding can be obvious when blood is present in stool or vomit, or the bleeding can be hidden where the symptoms are a feeling of lightheadedness or difficulty in breathing, fainting, chest or abdominal pain. Continue reading →

Pharmacokinetic/Pharmacodynamic Relationship in Humans Similar to Preclinical Findings Data Support Progression to Phase 2 Clinical Trial in Patients with Obstructive Hypertrophic Cardiomyopathy to Begin in Q4 2019 SOUTH SAN FRANCISCO, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced data from the Phase 1 study of CK-3773274 (CK-274) were presented in a poster session at the HFSA 23rd Annual Scientific Meeting in Philadelphia. The study met its primary and secondary objectives to assess the safety and tolerability of single and multiple oral doses of CK-274, describe the pharmacokinetics (PK) of CK-274 and its pharmacodynamic effects (PD) as measured by echocardiography, as well as to characterize the PK/PD relationship with regards to cardiac function Continue reading →

Dublin, Sept. 16, 2019 (GLOBE NEWSWIRE) -- The "Nitric Oxide - Therapeutics, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report contains information on the following: NO Pathways Role of NO in Physiology Role of NO in Disease Pharmacology Therapeutic Applications Evaluation of NO-based drugs Markets for NO-based Therapies Companies involved in NO therapeutics The report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Continue reading →

The formation of excess fibrous tissue in the heart, which underlies several heart diseases, could be prevented by inhibiting specific proteins that bind to RNA while its code is being translated Using cutting-edge technologies, researchers at Duke-NUS Medical School, Singapore, have developed the first genome-wide dataset on protein translation during fibroblast activation, revealing a network of RNA-binding proteins (RBPs) that play a key role in the formation of disease-causing fibrous tissue in the heart. Their findings, published in the journal Circulation, could help in the search for treatments for this condition. Continue reading →

-Second interim analysis from the Phase 3 SPARTAN study reporting updated overall survival results in patients with non-metastatic castration-resistant prostate cancer treated with ERLEADA (apalutamide) -Patient-reported outcomes from the Phase 3 TITAN study evaluating ERLEADA in patients with metastatic castration-sensitive prostate cancer -Interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer and biallelic DNA-repair gene defects, featured as late-breaking abstract RARITAN, N.J., Sept. 17, 2019 /PRNewswire/ --The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from its prostate cancer and solid tumor portfolios will be featured at the European Society for Medical Oncology (ESMO) Annual Congress 2019, taking place September 27 to October 1 in Barcelona, Spain. Among Janssen's 12 accepted abstracts are an oral presentation reporting updated overall survival results from the ERLEADA (apalutamide) Phase 3 SPARTAN study in patients with non-metastatic castration-resistant prostate cancer (nmCRPC); patient-reported outcomes from the ERLEADA Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC), demonstrating preservation of overall health-related quality of life; and a late-breaking interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Continue reading →

Sept. 12, 2019 10:31 UTC CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults. mRNA-1944 encodes for an antibody (CHKV-24) with activity against chikungunya virus Continue reading →

Pharmacokinetics is currently defined as the branch of pharmacology concerned with the study of the time course of drug distribution, absorption, metabolism and excretion. Pharmacokinetics is derived from the Greek word pharmacon (drug) and kineticos (motion) Drugs aims to prevent, cure or control various diseases states. To achieve this goal suitable concentration of medicine must be delivered to the target tissues so that will be beneficial, yet nontoxic levels are obtained Continue reading →

Microbiomes are used for metabolism and immunity. In the human body, microbes are used as a factory to produce drugs, a machine for perforated action, a vehicle for drug delivery and are sometimes considered drugs. Microbiomes are used to treat various diseases, such as autoimmune diseases and gastrointestinal diseases Continue reading →

Pharmacogenomics (PGx) Market Report has newly added to its massive repository. Different industry-specific methods have been used for analyzing the market carefully Continue reading →